Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Pooling RT-qPCR testing for SARS-CoV-2 in 1000 individuals of healthy and infection-suspected patients.

Tytuł:
Pooling RT-qPCR testing for SARS-CoV-2 in 1000 individuals of healthy and infection-suspected patients.
Autorzy:
Hirotsu Y; Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan. .
Maejima M; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Shibusawa M; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Nagakubo Y; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.; Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Hosaka K; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Amemiya K; Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Sueki H; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Hayakawa M; Division of Microbiology in Clinical Laboratory, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Mochizuki H; Genome Analysis Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.; Department of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Tsutsui T; Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Kakizaki Y; Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Miyashita Y; Lung Cancer and Respiratory Disease Center, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.
Omata M; Department of Gastroenterology, Yamanashi Central Hospital, 1-1-1 Fujimi, Kofu, Yamanashi, Japan.; The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Źródło:
Scientific reports [Sci Rep] 2020 Nov 03; Vol. 10 (1), pp. 18899. Date of Electronic Publication: 2020 Nov 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Clinical Laboratory Techniques/*methods
Mass Screening/*methods
Reverse Transcriptase Polymerase Chain Reaction/*methods
Betacoronavirus/genetics ; Betacoronavirus/pathogenicity ; COVID-19 Testing ; Clinical Laboratory Techniques/standards ; Coronavirus Infections/diagnosis ; Coronavirus Infections/epidemiology ; Humans ; Limit of Detection ; Mass Screening/standards ; Reproducibility of Results ; Respiratory Mucosa/virology ; Reverse Transcriptase Polymerase Chain Reaction/standards ; SARS-CoV-2
References:
JAMA. 2020 May 19;323(19):1912-1914. (PMID: 32221579)
N Engl J Med. 2020 Mar 26;382(13):1199-1207. (PMID: 31995857)
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307. (PMID: 32074516)
Proc Natl Acad Sci U S A. 2020 Apr 21;117(16):9122-9126. (PMID: 32245814)
J Clin Microbiol. 1998 Dec;36(12):3624-8. (PMID: 9817885)
Science. 2020 May 1;368(6490):489-493. (PMID: 32179701)
Am J Clin Pathol. 2020 May 5;153(6):715-718. (PMID: 32304208)
JAMA. 2020 May 12;323(18):1775-1776. (PMID: 32203977)
J Virol Methods. 2020 Oct;284:113926. (PMID: 32650037)
Nature. 2020 Jul;583(7817):504-505. (PMID: 32651561)
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
J Med Virol. 1996 Jul;49(3):218-22. (PMID: 8818968)
JAMA. 2020 May 19;323(19):1967-1969. (PMID: 32250394)
Int J Infect Dis. 2020 Oct;99:397-402. (PMID: 32800855)
Euro Surveill. 2020 Apr;25(14):. (PMID: 32290904)
J Clin Virol. 2020 Aug;129:104543. (PMID: 32663787)
Nat Med. 2020 May;26(5):672-675. (PMID: 32296168)
Lancet. 1999 Jan 30;353(9150):359-63. (PMID: 9950441)
Transfusion. 1998 Oct;38(10):905-7. (PMID: 9767739)
Lancet Infect Dis. 2020 May;20(5):565-574. (PMID: 32213337)
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1105-1106. (PMID: 32299521)
AIDS. 2000 Dec 1;14(17):2751-7. (PMID: 11125894)
Entry Date(s):
Date Created: 20201104 Date Completed: 20201120 Latest Revision: 20201218
Update Code:
20240105
PubMed Central ID:
PMC7641135
DOI:
10.1038/s41598-020-76043-z
PMID:
33144632
Czasopismo naukowe
Severe acute respiratory coronavirus 2 (SARS-CoV-2) testing reagents are expected to become scarce worldwide. However, little is known regarding whether pooling of samples accurately detects SARS-CoV-2. To validate the feasibility of pooling samples, serial dilution analysis and spike-in experiments were conducted using synthetic DNA and nucleic acids extracted from SARS-CoV-2-positive and -negative patients. Furthermore, we studied 1000 individuals, 667 of whom were "healthy" individuals (195 healthcare workers and 472 hospitalized patients with disorders other than COVID-19 infection), and 333 infection-suspected patients with cough and fever. Serial dilution analysis showed a limit of detection of around 10-100 viral genome copies according to the protocol of the National Institute of Infectious Diseases, Japan. Spike-in experiments demonstrated that RT-qPCR detected positive signals in pooled samples with SARS-CoV-2-negative and -positive patients at 5-, 10-, 20-fold dilutions. By screening with this pooling strategy, by the end of April 2020 there were 12 SARS-CoV-2-positive patients in 333 infection-suspected patients (3.6%) and zero in 667 "healthy" controls. We obtained these results with a total of 538 runs using the pooling strategy, compared with 1000 standard runs. In a prospective study, we successfully detected SARS-CoV-2 using 10- to 20-fold diluted samples of nasopharyngeal swabs from eighteen COVID-19 patients with wide ranges of viral load. Pooling sample is feasible for conserving test reagents and detecting SARS-CoV-2 in clinical settings. This strategy will help us to research the prevalence infected individuals and provide infected-status information to prevent the spread of the virus and nosocomial transmission.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies